Clinical Trial: Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer

U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07199764) titled 'Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer' on Sept. 22.

Brief Summary: Phase II, open-label, single-arm study of CD40/Dectin-1 immunotherapy as maintenance treatment in patients with unresectable pancreatic ductal adenocarcinoma (PDA) who have not progressed following 4-6 months of first line (1L) chemotherapy.

Study Start Date: Oct., 2025

Study Type: INTERVENTIONAL

Condition: Pancreatic Ductal Adenocarcinoma

Intervention: DRUG: Odetiglucan

Odetiglucan 4 mg/kg IV every 3 weeks

DRUG: Mitazalimab

Mitazalimab 0.9 mg/kg IV every 3 weeks

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Un...